SpringWorks Therapeutics has seen its share price rise on news that GSK is expanding their partnership for its investigational anti-tumor product, nirogacestat, and taking a $75m direct stake in the company.
Confidence In SpringWorks Grows With Expanded GSK Deal And Nirogacestat Plans
On Track For First Approval In 2023
SpringWorks is on course to bring nirogacestat to market by next year – and could play a pivotal role in making BCMA-targeting drugs a success.
More from Archive
More from Scrip
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.